{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:49:58Z","timestamp":1790948998554,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The PARADIGHM registry of adult and pediatric patients with chronic hypoparathyroidism evaluates the long-term safety and effectiveness of treatment with recombinant human parathyroid hormone, rhPTH(1-84), and describes the clinical disease course under conditions of routine clinical practice. In this first report, we detail the registry protocol and describe the baseline characteristics of two adult patient cohorts from an interim database analysis. One cohort after study entry were prescribed rhPTH(1-84), and the other cohort received conventional therapy of calcium and active vitamin D.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An observational study of patients with chronic hypoparathyroidism in North America and Europe, collecting data for \u226510 years per patient. Main outcome measures were baseline patient demographics, clinical characteristics, medications, and disease outcome variables of symptoms, biochemical parameters, and health assessments. Baseline is the enrollment assessment for all variables except biochemical measurements in patients treated with rhPTH(1-84); those measurements were the most recent value before the first rhPTH(1-84) dose. Exclusion criteria applied to the analysis of specified outcomes included pediatric patients, patients who initiated rhPTH(1-84) prior to enrollment, and those who received rhPTH(1-34). Clinically implausible biochemical outlier data were excluded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>As of 30 June 2019, data of 737 patients were analyzed from 64 centers; 587 (80%) were women, mean \u00b1 SD age 49.1\u00b116.45 years. At enrollment, symptoms reported for patients later prescribed rhPTH(1-84) (n=60) and those who received conventional therapy (n=571), respectively, included fatigue (51.7%, 40.1%), paresthesia (51.7%, 29.6%), muscle twitching (48.3%, 21.9%), and muscle cramping (41.7%, 33.8%). Mean serum total calcium, serum phosphate, creatinine, and estimated glomerular filtration rate were similar between cohorts. Health-related quality of life (HRQoL) 36-item Short Form Health Survey questionnaire scores for those later prescribed rhPTH(1-84) were generally lower than those for patients in the conventional therapy cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>At enrollment, based on symptoms and HRQoL, a greater percentage of patients subsequently prescribed rhPTH(1-84) appeared to have an increased burden of disease than those who received conventional therapy despite having normal biochemistry measurements. PARADIGHM will provide valuable real-world insights on the clinical course of hypoparathyroidism in patients treated with rhPTH(1-84) or conventional therapy in routine clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EUPAS16927, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01922440\">NCT01922440<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00888-2","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T18:02:41Z","timestamp":1637431361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics"],"prefix":"10.1186","volume":"21","author":[{"given":"Neil","family":"Gittoes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rejnmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Ing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigridur","family":"Bj\u00f6rnsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores M.","family":"Shoback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara J.","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinggao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Germak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,20]]},"reference":[{"key":"888_CR1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke B, Thakker RV, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101:2273\u201383.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D. Hypoparathyroidism. N Engl J Med. 2008;359:391\u2013403.","journal-title":"N Engl J Med."},{"key":"888_CR3","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1210\/jc.2015-3909","volume":"101","author":"DM Shoback","year":"2016","unstructured":"Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101:2300\u201312.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR4","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-18-0609","volume":"180","author":"AA Khan","year":"2019","unstructured":"Khan AA, Koch C, Van Uum SHM, Baillargeon JP, Bollerslev J, Brandi ML, et al. Standards of care for hypoparathyroidism in adults: a Canadian and international consensus. Eur J Endocrinol. 2019;180:P1\u2013P22.","journal-title":"Eur J Endocrinol."},{"key":"888_CR5","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/jbmr.2004","volume":"28","author":"J Powers","year":"2013","unstructured":"Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28:2570\u20136.","journal-title":"J Bone Miner Res."},{"key":"888_CR6","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, et al. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173:G1\u2013G120.","journal-title":"Eur J Endocrinol."},{"key":"888_CR7","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1210\/jc.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507\u201314.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR8","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","volume":"28","author":"L Underbjerg","year":"2013","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28:2277\u201385.","journal-title":"J Bone Miner Res."},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1007\/s12325-019-01102-5","volume":"36","author":"K Iqbal","year":"2019","unstructured":"Iqbal K, Dass N, Gip C, Vila J, Rylands AJ, Marelli C. Defining the characteristics of chronic hypoparathyroidism not adequately controlled on conventional therapy: consensus findings of three European delphi panels. Adv Ther. 2019;36:3007\u201316.","journal-title":"Adv Ther."},{"key":"888_CR10","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40618-018-0857-5","volume":"41","author":"A Meola","year":"2018","unstructured":"Meola A, Vignali E, Matrone A, Cetani F, Marcocci C. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest. 2018;41:1221\u20136.","journal-title":"J Endocrinol Invest."},{"key":"888_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jbmr.3623","volume":"34","author":"G Tabacco","year":"2019","unstructured":"Tabacco G, Naciu AM, Maggi D, Santonati A, Pedone C, Cesareo R, et al. Cardiovascular autonomic neuropathy as a new complication of postsurgical chronic hypoparathyroidism. J Bone Miner Res. 2019;34:475\u201381.","journal-title":"J Bone Miner Res."},{"key":"888_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cen.14128","volume":"92","author":"H Siggelkow","year":"2020","unstructured":"Siggelkow H, Clarke BL, Germak J, Marelli C, Chen K, Dahl-Hansen H, et al. Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey. Clin Endocrinol (Oxf). 2020;92:159\u201368.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"888_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146:215\u201322.","journal-title":"Eur J Endocrinol."},{"key":"888_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4158\/EP13328.OR","volume":"20","author":"N Hadker","year":"2014","unstructured":"Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract. 2014;20:671\u20139.","journal-title":"Endocr Pract."},{"key":"888_CR15","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, Lovas K, Debowska A, Eriksen EF, Evang JA, Fossum C, et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016;101:3045\u201353.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR16","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1210\/jc.2013-1239","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ, Irani D, Tulley A, Sliney J Jr, et al. The effect of PTH(1-84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98:2356\u201361.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","volume":"25","author":"T Sikjaer","year":"2014","unstructured":"Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25:1717\u201326.","journal-title":"Osteoporos Int."},{"key":"888_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11657-020-00759-8","volume":"15","author":"S Hepsen","year":"2020","unstructured":"Hepsen S, Akhanli P, Sakiz D, Sencar ME, Ucan B, Unsal IO, et al. The effects of patient and disease-related factors on the quality of life in patients with hypoparathyroidism. Arch Osteoporos. 2020;15:75.","journal-title":"Arch Osteoporos."},{"key":"888_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/cen.13593","volume":"88","author":"L Underbjerg","year":"2018","unstructured":"Underbjerg L, Sikjaer T, Rejnmark L. Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf). 2018;88:838\u201347.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"888_CR20","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1210\/jc.2014-2267","volume":"99","author":"NE Cusano","year":"2014","unstructured":"Cusano NE, Rubin MR, McMahon DJ, Irani D, Anderson L, Levy E, et al. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99:3694\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR21","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/jbmr.2812","volume":"31","author":"T Sikjaer","year":"2016","unstructured":"Sikjaer T, Moser E, Rolighed L, Underbjerg L, Bislev LS, Mosekilde L, et al. Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J Bone Miner Res. 2016;31:1440\u20138.","journal-title":"J Bone Miner Res."},{"key":"888_CR22","unstructured":"Natpar\u00ae parathyroid hormone. Dublin: Shire Pharmaceuticals Ireland Limited; 2019."},{"key":"888_CR23","unstructured":"Natpara\u00ae parathyroid hormone. Lexington: Shire-NPS Pharmaceuticals, Inc.; 2020."},{"key":"888_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomized, phase 3 study. Lancet Diabetes Endocrinol. 2013;1:275\u201383 erratum: Lancet Diabetes Endocrinol. 2014;2(1):e3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"888_CR25","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/jbmr.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. Hypoparathyroid Study Group. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26:2358\u201370.","journal-title":"J Bone Miner Res."},{"key":"888_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1210\/jc.2012-2984","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98:137\u201344.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR27","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1210\/jc.2019-01010","volume":"104","author":"M Mannstadt","year":"2019","unstructured":"Mannstadt M, Clarke BL, Bilezikian JP, Bone H, Denham D, Levine MA, et al. Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab. 2019;104:5136\u201347.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR28","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1210\/jc.2015-4135","volume":"101","author":"MR Rubin","year":"2016","unstructured":"Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016;101:2742\u201350.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR29","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1210\/jc.2019-00893","volume":"104","author":"YD Tay","year":"2019","unstructured":"Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R, et al. Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2019;104:5601\u201310.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/02813430902808643","volume":"27","author":"M Arne","year":"2009","unstructured":"Arne M, Janson C, Janson S, Boman G, Lindqvist U, Berne C, et al. Physical activity and quality of life in subjects with chronic disease: chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. Scand J Prim Health Care. 2009;27:141\u20137.","journal-title":"Scand J Prim Health Care."},{"key":"888_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2040620714560305","volume":"6","author":"MJ Mauro","year":"2015","unstructured":"Mauro MJ, Davis C, Zyczynski T, Khoury HJ. The role of observational studies in optimizing the clinical management of chronic myeloid leukemia. Ther Adv Hematol. 2015;6:3\u201314.","journal-title":"Ther Adv Hematol."},{"key":"888_CR32","first-page":"18","volume":"7","author":"DR Spigel","year":"2010","unstructured":"Spigel DR. The value of observational cohort studies for cancer drugs. Biotechnol Healthc. 2010;7:18\u201324.","journal-title":"Biotechnol Healthc."},{"key":"888_CR33","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med."},{"key":"888_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/PROM.S179310","volume":"10","author":"T Coles","year":"2019","unstructured":"Coles T, Chen K, Nelson L, Harris N, Vera-Llonch M, Krasner A, et al. Psychometric evaluation of the hypoparathyroidism symptom diary. Patient Relat Outcome Meas. 2019;10:25\u201336.","journal-title":"Patient Relat Outcome Meas."},{"key":"888_CR35","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s12325-019-00999-2","volume":"36","author":"S Martin","year":"2019","unstructured":"Martin S, Chen K, Harris N, Vera-Llonch M, Krasner A. Development of a patient-reported outcome measure for chronic hypoparathyroidism. Adv Ther. 2019;36:1999\u20132009.","journal-title":"Adv Ther."},{"key":"888_CR36","unstructured":"Reilly Associates. Work productivity and activity impairment questionnaire: specific health problem v2.0 (WPAI:SHP). http:\/\/www.reillyassociates.net\/WPAI_SHP.html. Accessed Feb 2021."},{"key":"888_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics."},{"key":"888_CR38","doi-asserted-by":"publisher","unstructured":"Hamdy NAT, Decallonne B, Evenepoel P, Gruson D, van Vlokhoven-Verhaegh L. Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. J Endocrinol Invest. 2020. https:\/\/doi.org\/10.1007\/s40618-020-01442-y.","DOI":"10.1007\/s40618-020-01442-y"},{"key":"888_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cen.13895","volume":"90","author":"T Vadiveloo","year":"2019","unstructured":"Vadiveloo T, Donnan PT, Leese CJ, Abraham KJ, Leese GP. Increased mortality and morbidity in patients with chronic hypoparathyroidism: a population-based study. Clin Endocrinol (Oxf). 2019;90:285\u201392.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"888_CR40","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390.","journal-title":"Clin Epidemiol."},{"key":"888_CR41","doi-asserted-by":"publisher","unstructured":"Alalawi Y, El Werfalli R, Abu Alrob H, Braga M, Millar A, Punthakee Z, et al. An overview of the etiology, clinical manifestations, management strategies, and complications of hypoparathyroidism from the Canadian National Hypoparathyroidism Registry. J Endocr Soc. 2019;3(Suppl 1):MON-LB1091.\u00a0https:\/\/doi.org\/10.1210\/js.2019-MON-LB091.","DOI":"10.1210\/js.2019-MON-LB091"},{"key":"888_CR42","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/j.clinthera.2017.08.011","volume":"39","author":"JP Bilezikian","year":"2017","unstructured":"Bilezikian JP, Clarke BL, Mannstadt M, Rothman J, Vokes T, Lee HM, et al. Safety and efficacy of recombinant human parathyroid hormone in adults with hypoparathyroidism randomly assigned to receive fixed 25-\u03bcg or 50-\u03bcg daily doses. Clin Ther. 2017;39:2096\u2013102.","journal-title":"Clin Ther."},{"key":"888_CR43","doi-asserted-by":"crossref","unstructured":"Bohrer T, Paul J, Krannich H, Hasse C, Elert O. The Wuerzburg scale: a new classification system for permanent postoperative hypoparathyroidism. Eur Surg. 2007;39-44.","DOI":"10.1007\/s10353-006-0306-0"},{"key":"888_CR44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/jc.2017-01471","volume":"103","author":"TJ Vokes","year":"2018","unstructured":"Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Lakatos P, Chen K, et al. Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab. 2018;103:722\u201331.","journal-title":"J Clin Endocrinol Metab."},{"key":"888_CR45","doi-asserted-by":"crossref","unstructured":"Chen K, Krasner A, Li N, Xiang CQ, Totev T, Xie J. Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review. J Med Econ. 2019:1\u201312.","DOI":"10.1080\/13696998.2019.1624081"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00888-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00888-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00888-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T18:02:48Z","timestamp":1637431368000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00888-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,20]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00888-2","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,20]]},"assertion":[{"value":"19 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board\/Independent Ethics Committee\/Research Ethics Board at each participating site. Central Institutional Review Boards were utilized by 1 UK, 4 Swedish, and 19 US sites; Institutional Review Boards were utilized by 27 US sites. The patient, the parent(s) of a pediatric patient, or a legally authorized representative is required to provide written informed consent. The study is being conducted in accordance with Good Pharmacoepidemiology Practice as described by the International Society for Pharmacoepidemiology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NG and SH have served as an advisory board member and consultant for Shire, a Takeda company. LR has served as an advisory board member, research investigator, and speaker for Shire, a Takeda company. SWI has served as an advisory board member and research investigator for Shire, a Takeda company, and served as research investigator for Amgen Inc., Chugai Pharmaceutical Co., Ltd, Radius Health Inc., and Ultragenyx Pharmaceutical. SB and AAK have served as research investigators for Shire, a Takeda company. MLB has served as a research investigator and speaker for Shire, a Takeda company. LCH has served as a research investigator and received honoraria for advisory boards from Shire, a Takeda company, and received honoraria for advisory boards from Ascendis Pharma, Alexion Pharmaceuticals Inc., Amgen Inc., Kyowa Kirin International, and USB. PH has served as an advisory board member, consultant, research investigator, and speaker for Shire, a Takeda company. MAL, DMS, and TV have served as an advisory board member, consultant, and research investigator for Shire, a Takeda company. PZ and JG are employed by Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA. MM has served as an advisory board member, consultant, and research investigator for Shire, a Takeda company, as consultant and research investigator for Chugai Pharmaceutical Co., Ltd, and as consultant for Amolyt Pharma. CM is employed by Takeda Pharmaceuticals International AG, Zurich, Switzerland. BLC has served as consultant and research investigator for Shire, a Takeda company, and has received grant funding from Ascendis Pharma and Chugai Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}